I don't understand it at all. It looks like highly illegal manipulation. Feel bad for all the bag holders as this was a good play.
Management really f'd this up by not closely scrutinizing their own data the first time they released the results, but that may have been intentional on their end.
Either way, something very "wrong" is happening here.
Management really f'd this up by not closely scrutinizing their own data the first time they released the results, but that may have been intentional on their end.
Either way, something very "wrong" is happening here.
Recent AKBA News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 11:24:30 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 11:05:53 AM
- Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights • GlobeNewswire Inc. • 05/07/2026 11:00:00 AM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/04/2026 08:05:00 PM
- Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology • GlobeNewswire Inc. • 05/04/2026 12:00:00 PM
- Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights • GlobeNewswire Inc. • 04/30/2026 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 08:13:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 08:12:53 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/15/2026 08:08:50 PM
- Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 • GlobeNewswire Inc. • 04/13/2026 12:00:00 PM
- Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium • GlobeNewswire Inc. • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:06:54 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:05:32 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/02/2026 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2026 08:48:09 PM
- Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors • GlobeNewswire Inc. • 04/01/2026 08:05:00 PM
- Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 • GlobeNewswire Inc. • 03/19/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 11:55:46 PM
- Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference • GlobeNewswire Inc. • 03/03/2026 01:00:00 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/02/2026 09:05:00 PM
- Akebia Therapeutics posts mixed Q4 results as revenue beats expectations despite EPS miss • IH Market News • 02/26/2026 03:57:19 PM
- Akebia tops Q4 revenue expectations as Vafseo momentum strengthens outlook • IH Market News • 02/26/2026 03:48:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:04:39 PM
- Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights • GlobeNewswire Inc. • 02/26/2026 12:00:00 PM
- Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights • GlobeNewswire Inc. • 02/19/2026 01:00:00 PM
